NCT00748904

Rifaximin Versus Lactulose in Renal Failure

A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Weill Medical College of Cornell University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, if one is associated with lower breath hydrogen and methane levels.

Conditions

• Liver Cirrhosis
• Renal Failure

Interventions

Type	Name	Description
DRUG	Rifaximin	400 mg orally
DRUG	Lactulose	20 grams titrate to 2-3 bowel movements in one day

Timeline

• Start date: 2008-06-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2008-09-09
• Last updated: 2022-02-08

Locations

1 site across 1 country: United States